ES2303565T3
(es)
*
|
2001-11-01 |
2008-08-16 |
Janssen Pharmaceutica Nv |
Derivados de aminobenzamida como inhibidores de la glucogeno sintasa cinasa 3beta.
|
TWI329105B
(en)
|
2002-02-01 |
2010-08-21 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidinediamine compounds and their uses
|
GB0206215D0
(en)
*
|
2002-03-15 |
2002-05-01 |
Novartis Ag |
Organic compounds
|
MXPA05001096A
(es)
*
|
2002-07-29 |
2005-11-23 |
Rigel Pharmaceuticals Inc |
Metodos para tratamiento o prevencion de enfermedades autoinmunes con compuestos de 2,4-diamino-pirimidina.
|
WO2004056807A1
(en)
|
2002-12-20 |
2004-07-08 |
Pfizer Products Inc. |
Pyrimidine derivatives for the treatment of abnormal cell growth
|
US7109337B2
(en)
|
2002-12-20 |
2006-09-19 |
Pfizer Inc |
Pyrimidine derivatives for the treatment of abnormal cell growth
|
GB0305929D0
(en)
*
|
2003-03-14 |
2003-04-23 |
Novartis Ag |
Organic compounds
|
US7172633B2
(en)
|
2003-06-16 |
2007-02-06 |
L'ORéAL S.A. |
Lightening dye composition comprising at least one cationic direct dye containing mixed chromophores
|
US7201779B2
(en)
|
2003-06-16 |
2007-04-10 |
L'oreal S.A. |
Dye composition comprising at least one direct dye containing mixed chromophores
|
US7442698B2
(en)
|
2003-07-24 |
2008-10-28 |
Amgen Inc. |
Substituted heterocyclic compounds and methods of use
|
KR20120062863A
(ko)
*
|
2003-07-30 |
2012-06-14 |
리겔 파마슈티칼스, 인크. |
자가면역 질환의 치료 또는 예방에 사용하기 위한 2,4-피리미딘디아민 화합물
|
CA2533320A1
(en)
*
|
2003-08-15 |
2006-02-24 |
Novartis Ag |
2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
|
GB0321710D0
(en)
*
|
2003-09-16 |
2003-10-15 |
Novartis Ag |
Organic compounds
|
EP1663992A1
(en)
*
|
2003-09-18 |
2006-06-07 |
Novartis AG |
2,4-di (phenylamino) pyrimidines useful in the treatment of proliferative disorders
|
US20050075358A1
(en)
*
|
2003-10-06 |
2005-04-07 |
Carboni Joan M. |
Methods for treating IGF1R-inhibitor induced hyperglycemia
|
AU2004282219C1
(en)
*
|
2003-10-15 |
2009-12-17 |
Osi Pharmaceuticals, Inc. |
Imidazo [1, 5 - a] pyrazine tyrosine kinase inhibitors
|
EA011402B1
(ru)
*
|
2004-01-23 |
2009-02-27 |
Эмджен Инк. |
Азотсодержащие гетероциклические производные и их фармацевтические применения
|
US7288121B2
(en)
|
2004-02-27 |
2007-10-30 |
L'oreal S.A. |
Composition comprising at least one mixed dye comprising at least one chromophore chosen from compounds of the methine family and/or the carbonyl family, dyeing process and kit, and mixed dyes
|
US7303591B2
(en)
|
2004-02-27 |
2007-12-04 |
L'oreal S.A. |
Composition comprising at least one mixed dye comprising at least two chromophores of (hetero) aromatic nitro or cyclic azine type, dyeing process, and mixed dyes
|
SG163576A1
(en)
|
2004-04-02 |
2010-08-30 |
Osi Pharm Inc |
6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
|
EP1751142A1
(en)
|
2004-05-14 |
2007-02-14 |
Pfizer Products Incorporated |
Pyrimidines derivatives for the treatment of abnormal cell growth
|
JP2007537235A
(ja)
|
2004-05-14 |
2007-12-20 |
ファイザー・プロダクツ・インク |
異常細胞増殖の治療用ピリミジン誘導体
|
MXPA06013165A
(es)
|
2004-05-14 |
2007-02-13 |
Pfizer Prod Inc |
Derivados de pirimidina para el tratamiento de crecimiento de celulas anormal.
|
AR053090A1
(es)
|
2004-07-20 |
2007-04-25 |
Osi Pharm Inc |
Imidazotriazinas como inhibidores de proteina quinasas y su uso para la preparacion de medicamentos
|
EP1797054A2
(en)
|
2004-08-02 |
2007-06-20 |
OSI Pharmaceuticals, Inc. |
Aryl-amino substituted pyrrolopyrimidine multi-kinase inhibiting compounds
|
GB0419160D0
(en)
|
2004-08-27 |
2004-09-29 |
Novartis Ag |
Organic compounds
|
EP1799652A1
(en)
*
|
2004-10-13 |
2007-06-27 |
Wyeth |
N-benzenesulfonyl substituted anilino-pyrimidine analogs
|
CA2584295C
(en)
*
|
2004-11-24 |
2014-08-26 |
Rigel Pharmaceuticals, Inc. |
Spiro-2, 4-pyrimidinediamine compounds and their uses
|
WO2006074057A2
(en)
*
|
2004-12-30 |
2006-07-13 |
Exelixis, Inc. |
Pyrimidine derivatives as kinase modulators and method of use
|
EP2161275A1
(en)
|
2005-01-19 |
2010-03-10 |
Rigel Pharmaceuticals, Inc. |
Prodrugs of 2,4-pyrimidinediamine compounds and their uses
|
US20080161278A1
(en)
*
|
2005-03-23 |
2008-07-03 |
Astrazeneca Ab |
2-Azetidinyl-4-(1H-Pyrazol-3-Ylamino) Pyrimidines as Inhibitors of Insulin-Like Growth Factor-1 Receptor Activity
|
CA2602372A1
(en)
*
|
2005-04-05 |
2006-10-12 |
Astrazeneca Ab |
Pyrimidine derivatives for use as anticancer agents
|
GB0506886D0
(en)
*
|
2005-04-05 |
2005-05-11 |
Astrazeneca Ab |
Chemical compounds
|
DE102005016634A1
(de)
*
|
2005-04-12 |
2006-10-19 |
Merck Patent Gmbh |
Neuartige Aza-Hetercyclen als Kinase-Inhibitoren
|
GB0507347D0
(en)
*
|
2005-04-12 |
2005-05-18 |
Astrazeneca Ab |
Chemical compounds
|
WO2007027238A2
(en)
*
|
2005-05-03 |
2007-03-08 |
Rigel Pharmaceuticals, Inc. |
Jak kinase inhibitors and their uses
|
WO2006133426A2
(en)
|
2005-06-08 |
2006-12-14 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
US20070203161A1
(en)
|
2006-02-24 |
2007-08-30 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
FR2888239B1
(fr)
*
|
2005-07-11 |
2008-05-09 |
Sanofi Aventis Sa |
Nouveaux derives de 2,4-dianilinopyrimidines, leur preparation, a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
|
AU2006268531A1
(en)
*
|
2005-07-11 |
2007-01-18 |
Sanofi-Aventis |
Novel 2,4-dianilinopyrimidine derivatives, the preparation thereof, their use as medicaments, pharmaceutical compositions and, in particular, as IKK inhibitors
|
US7566721B2
(en)
*
|
2005-08-08 |
2009-07-28 |
Osi Pharmaceuticals, Inc. |
Substituted thienol[2,3-d]pyrimidines as kinase inhibitors
|
JP2009508833A
(ja)
*
|
2005-09-16 |
2009-03-05 |
アストラゼネカ アクチボラグ |
Igf−1rチロシンキナーゼ活性の阻害のためのピリミジン誘導体類
|
ES2374450T3
(es)
|
2005-09-20 |
2012-02-16 |
OSI Pharmaceuticals, LLC |
Marcadores biológicos predictivos de respuesta anticancerígena para inhibidores de cinasa del receptor del factor de crecimiento 1 similar a insulina.
|
AR057960A1
(es)
*
|
2005-12-02 |
2007-12-26 |
Osi Pharm Inc |
Inhibidores de proteina quinasa biciclicos
|
US8575164B2
(en)
*
|
2005-12-19 |
2013-11-05 |
OSI Pharmaceuticals, LLC |
Combination cancer therapy
|
GB0526246D0
(en)
*
|
2005-12-22 |
2006-02-01 |
Novartis Ag |
Organic compounds
|
TW200736232A
(en)
*
|
2006-01-26 |
2007-10-01 |
Astrazeneca Ab |
Pyrimidine derivatives
|
US8962643B2
(en)
|
2006-02-24 |
2015-02-24 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the JAK pathway
|
KR20090019011A
(ko)
*
|
2006-06-15 |
2009-02-24 |
베링거 인겔하임 인터내셔날 게엠베하 |
단백질 키나아제 c-알파의 억제제로서의 2-아닐리노-4-(헤테로사이클릭)아미노-피리미딘
|
AU2007257701A1
(en)
|
2006-06-15 |
2007-12-21 |
Boehringer Ingelheim International Gmbh |
2-anilino-4-aminoalkyleneaminopyrimidines
|
WO2008005538A2
(en)
|
2006-07-05 |
2008-01-10 |
Exelixis, Inc. |
Methods of using igf1r and abl kinase modulators
|
CA2673125C
(en)
*
|
2006-10-19 |
2015-04-21 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
EP2222647B1
(en)
|
2006-10-23 |
2015-08-05 |
Cephalon, Inc. |
Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and c-met inhibitors
|
EP2537830A1
(en)
|
2006-12-08 |
2012-12-26 |
Irm Llc |
Compounds and compositions as protein kinase inhibitors
|
JP5622393B2
(ja)
|
2006-12-15 |
2014-11-12 |
アブラクシスバイオサイエンス リミテッド ライアビリティー カンパニー |
トリアジン誘導体類及びそれらの治療応用
|
CL2008000864A1
(es)
*
|
2007-03-27 |
2009-01-16 |
Astrazeneca Ab |
Compuestos derivados de pirimidina; composicion farmaceutica que comprende a dichos compuestos; procedimiento de preparacion de la composicion farmaceutica; y su uso para enfermedades relacionadas con el factor de crecimiento analogo a la insulina (igf).
|
WO2009010794A1
(en)
*
|
2007-07-19 |
2009-01-22 |
Astrazeneca Ab |
2,4-diamino-pyrimidine derivatives
|
AU2008289101A1
(en)
*
|
2007-08-17 |
2009-02-26 |
Icagen, Inc. |
Heterocycles as potassium channel modulators
|
US8431608B2
(en)
|
2007-08-17 |
2013-04-30 |
Icagen Inc. |
Heterocycles as potassium channel modulators
|
BRPI0815979A2
(pt)
*
|
2007-08-28 |
2017-06-13 |
Irm Llc |
compostos e composições com inibidores de quinase, bem como uso dos mesmos
|
JP2011509290A
(ja)
|
2008-01-11 |
2011-03-24 |
ナトコ ファーマ リミテッド |
抗癌剤としてのピラゾロ[3,4‐d]ピリミジン誘導体
|
JP2011510018A
(ja)
*
|
2008-01-18 |
2011-03-31 |
オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド |
癌治療のためのイミダゾピラジノール誘導体
|
EP2283020B8
(en)
*
|
2008-05-19 |
2012-12-12 |
OSI Pharmaceuticals, LLC |
Substituted imidazopyr-and imidazotri-azines
|
PE20100087A1
(es)
|
2008-06-25 |
2010-02-08 |
Irm Llc |
Compuestos y composiciones como inhibidores de cinasa
|
US8445505B2
(en)
|
2008-06-25 |
2013-05-21 |
Irm Llc |
Pyrimidine derivatives as kinase inhibitors
|
US8338439B2
(en)
|
2008-06-27 |
2012-12-25 |
Celgene Avilomics Research, Inc. |
2,4-disubstituted pyrimidines useful as kinase inhibitors
|
US11351168B1
(en)
|
2008-06-27 |
2022-06-07 |
Celgene Car Llc |
2,4-disubstituted pyrimidines useful as kinase inhibitors
|
EP3549934A1
(en)
|
2008-06-27 |
2019-10-09 |
Celgene CAR LLC |
Heteroaryl compounds and uses thereof
|
MX2011004824A
(es)
|
2008-11-07 |
2012-01-12 |
Triact Therapeutics Inc |
Uso de derivados de butano catecólico en terapia contra el cáncer.
|
WO2010072155A1
(zh)
*
|
2008-12-26 |
2010-07-01 |
复旦大学 |
一种嘧啶类衍生物及其制备方法和用途
|
US20120189641A1
(en)
|
2009-02-25 |
2012-07-26 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
US20110171124A1
(en)
|
2009-02-26 |
2011-07-14 |
Osi Pharmaceuticals, Inc. |
In situ methods for monitoring the EMT status of tumor cells in vivo
|
WO2010099138A2
(en)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
US8465912B2
(en)
|
2009-02-27 |
2013-06-18 |
OSI Pharmaceuticals, LLC |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
WO2010099363A1
(en)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
WO2010123792A1
(en)
|
2009-04-20 |
2010-10-28 |
Osi Pharmaceuticals, Inc. |
Preparation of c-pyrazine-methylamines
|
KR101705158B1
(ko)
|
2009-05-05 |
2017-02-09 |
다나-파버 캔서 인스티튜트 인크. |
Egfr 억제제 및 질환 치료방법
|
EP2427192A1
(en)
*
|
2009-05-07 |
2012-03-14 |
OSI Pharmaceuticals, LLC |
Use of osi-906 for treating adrenocortical carcinoma
|
US8486933B2
(en)
*
|
2009-05-27 |
2013-07-16 |
Abbvie Inc. |
Pyrimidine inhibitors of kinase activity
|
WO2010144394A1
(en)
|
2009-06-09 |
2010-12-16 |
Abraxis Bioscience, Llc |
Benzyl substituted triazine derivatives and their therapeutical applications
|
JP5785940B2
(ja)
|
2009-06-09 |
2015-09-30 |
アブラクシス バイオサイエンス, エルエルシー |
トリアジン誘導体類及びそれらの治療応用
|
JP6073677B2
(ja)
|
2009-06-12 |
2017-02-01 |
デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド |
縮合複素環式化合物およびそれらの使用
|
AU2010281404A1
(en)
*
|
2009-07-28 |
2012-02-09 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the JAK pathway
|
CA2784807C
(en)
|
2009-12-29 |
2021-12-14 |
Dana-Farber Cancer Institute, Inc. |
Type ii raf kinase inhibitors
|
CA2783656A1
(en)
|
2010-03-03 |
2011-09-09 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
EP2542893A2
(en)
|
2010-03-03 |
2013-01-09 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
WO2011112666A1
(en)
|
2010-03-09 |
2011-09-15 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
US20130137709A1
(en)
*
|
2010-05-05 |
2013-05-30 |
Nathanael S. Gray |
Compounds that modulate EGFR activity and methods for treating or preventing conditions therewith
|
JP5607241B2
(ja)
|
2010-05-21 |
2014-10-15 |
ケミリア・エービー |
新規ピリミジン誘導体
|
BR112013003388A2
(pt)
|
2010-08-10 |
2016-07-12 |
Celgene Avilomics Res Inc |
sal de besilato de um inibidor de btk
|
WO2012061303A1
(en)
|
2010-11-01 |
2012-05-10 |
Avila Therapeutics, Inc. |
Heteroaryl compounds and uses thereof
|
JP5957460B2
(ja)
|
2010-11-01 |
2016-07-27 |
セルジーン アヴィロミクス リサーチ, インコーポレイテッド |
複素環式化合物またはその使用
|
US8796255B2
(en)
|
2010-11-10 |
2014-08-05 |
Celgene Avilomics Research, Inc |
Mutant-selective EGFR inhibitors and uses thereof
|
WO2012116040A1
(en)
|
2011-02-22 |
2012-08-30 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
|
WO2012127032A1
(en)
|
2011-03-24 |
2012-09-27 |
Chemilia Ab |
Novel pyrimidine derivatives
|
WO2012149014A1
(en)
|
2011-04-25 |
2012-11-01 |
OSI Pharmaceuticals, LLC |
Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
|
AR088570A1
(es)
|
2011-10-28 |
2014-06-18 |
Celgene Avilomics Res Inc |
Metodos para tratar una enfermedad o trastorno relacionado con la tirosina quinasa de bruton
|
US9382239B2
(en)
|
2011-11-17 |
2016-07-05 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of c-Jun-N-terminal kinase (JNK)
|
US8993614B2
(en)
*
|
2012-03-15 |
2015-03-31 |
F. Hoffmann-La Roche Ag |
Substituted pyrrolidine-2-carboxamides
|
CN104284584B
(zh)
|
2012-03-15 |
2019-06-04 |
西建卡尔有限责任公司 |
表皮生长因子受体激酶抑制剂的盐
|
WO2013138495A1
(en)
|
2012-03-15 |
2013-09-19 |
Celgene Avilomics Research, Inc. |
Solid forms of an epidermal growth factor receptor kinase inhibitor
|
WO2013152252A1
(en)
|
2012-04-06 |
2013-10-10 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
EP2909194A1
(en)
|
2012-10-18 |
2015-08-26 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinase 7 (cdk7)
|
WO2014063054A1
(en)
|
2012-10-19 |
2014-04-24 |
Dana-Farber Cancer Institute, Inc. |
Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof
|
USRE48175E1
(en)
|
2012-10-19 |
2020-08-25 |
Dana-Farber Cancer Institute, Inc. |
Hydrophobically tagged small molecules as inducers of protein degradation
|
US9126950B2
(en)
|
2012-12-21 |
2015-09-08 |
Celgene Avilomics Research, Inc. |
Heteroaryl compounds and uses thereof
|
US9145387B2
(en)
|
2013-02-08 |
2015-09-29 |
Celgene Avilomics Research, Inc. |
ERK inhibitors and uses thereof
|
AU2014223548A1
(en)
|
2013-02-26 |
2015-10-15 |
Triact Therapeutics, Inc. |
Cancer therapy
|
WO2014151871A2
(en)
|
2013-03-14 |
2014-09-25 |
Tolero Pharmaceuticals, Inc. |
Jak2 and alk2 inhibitors and methods for their use
|
US10150742B2
(en)
|
2013-03-15 |
2018-12-11 |
President And Fellows Of Harvard College |
Substituted heterocyclic compounds for treating or preventing viral infections
|
US9492471B2
(en)
|
2013-08-27 |
2016-11-15 |
Celgene Avilomics Research, Inc. |
Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
|
US9381246B2
(en)
|
2013-09-09 |
2016-07-05 |
Triact Therapeutics, Inc. |
Cancer therapy
|
US20160264551A1
(en)
|
2013-10-18 |
2016-09-15 |
Syros Pharmaceuticals, Inc. |
Heteroaromatic compounds useful for the treatment of prolferative diseases
|
EP3057956B1
(en)
|
2013-10-18 |
2021-05-05 |
Dana-Farber Cancer Institute, Inc. |
Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7)
|
US9415049B2
(en)
|
2013-12-20 |
2016-08-16 |
Celgene Avilomics Research, Inc. |
Heteroaryl compounds and uses thereof
|
SG11201608242XA
(en)
|
2014-04-04 |
2016-10-28 |
Syros Pharmaceuticals Inc |
Inhibitors of cyclin-dependent kinase 7 (cdk7)
|
WO2015164604A1
(en)
|
2014-04-23 |
2015-10-29 |
Dana-Farber Cancer Institute, Inc. |
Hydrophobically tagged janus kinase inhibitors and uses thereof
|
WO2015164614A1
(en)
|
2014-04-23 |
2015-10-29 |
Dana-Farber Cancer Institute, Inc. |
Janus kinase inhibitors and uses thereof
|
CA2954764A1
(en)
|
2014-07-15 |
2016-01-21 |
Ontario Institute For Cancer Research |
Methods and devices for predicting anthracycline treatment efficacy
|
EP3179858B1
(en)
|
2014-08-13 |
2019-05-15 |
Celgene Car Llc |
Forms and compositions of an erk inhibitor
|
CN105601573B
(zh)
|
2014-11-24 |
2021-07-02 |
中国科学院上海药物研究所 |
2-氨基嘧啶类化合物及其药物组合物和应用
|
WO2016105528A2
(en)
|
2014-12-23 |
2016-06-30 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinase 7 (cdk7)
|
US10550121B2
(en)
|
2015-03-27 |
2020-02-04 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinases
|
AU2016276963C1
(en)
|
2015-06-12 |
2021-08-05 |
Dana-Farber Cancer Institute, Inc. |
Combination therapy of transcription inhibitors and kinase inhibitors
|
EP4019515A1
(en)
|
2015-09-09 |
2022-06-29 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinases
|
WO2017151409A1
(en)
|
2016-02-29 |
2017-09-08 |
University Of Florida Research Foundation, Incorporated |
Chemotherapeutic methods
|
JP2019533714A
(ja)
|
2016-11-11 |
2019-11-21 |
3−ブイ・バイオサイエンシーズ・インコーポレイテッド3−V Biosciences,Inc. |
脂質合成の複素環式モジュレーター
|
CN111683662B
(zh)
*
|
2017-08-28 |
2024-04-02 |
陈志宏 |
取代嘧啶类化合物及其药物组合物和治疗方法
|
AU2019247498A1
(en)
|
2018-04-05 |
2020-11-26 |
Sumitomo Pharma Oncology, Inc. |
AXL kinase inhibitors and use of the same
|
KR20210038906A
(ko)
|
2018-07-26 |
2021-04-08 |
스미토모 다이니폰 파마 온콜로지, 인크. |
비정상적 acvr1 발현과 연관된 질환을 치료하는 방법 및 그에 사용하기 위한 acvr1 억제제
|
CN111362928A
(zh)
*
|
2018-12-26 |
2020-07-03 |
上海喆邺生物科技有限公司 |
2,4-二氨基嘧啶衍生物
|
TW202115042A
(zh)
*
|
2019-06-21 |
2021-04-16 |
大陸商江蘇豪森藥業集團有限公司 |
芳基磷氧化物類衍生物抑制劑、其製備方法和應用
|
CN113549018B
(zh)
*
|
2020-04-24 |
2024-02-27 |
中国药科大学 |
蛋白激酶抑制剂及其衍生物,制备方法、药物组合物和应用
|
TW202237119A
(zh)
|
2020-12-10 |
2022-10-01 |
美商住友製藥腫瘤公司 |
Alk﹘5抑制劑和彼之用途
|
KR102560221B1
(ko)
*
|
2021-02-24 |
2023-07-27 |
서울대학교산학협력단 |
멀티키나제 억제제 및 이를 포함하는 암 예방 또는 치료용 조성물
|
KR20230155351A
(ko)
*
|
2022-05-03 |
2023-11-10 |
한국화학연구원 |
5-클로로-2,4-다이아미노피리미딘을 포함하는 키나아제 억제 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
|
CN115141150B
(zh)
*
|
2022-07-25 |
2024-04-26 |
南通大学 |
2,4,5-三取代嘧啶羟胺酰衍生物及其制备方法与应用
|